Lumos Pharma — NewLink Genetics — Q1 2019 Earnings Presentation
9 slides from Lumos Pharma's earnings presentation, May 8, 2019
Slide 1: First Quarter 2019 Financial Results
First Quarter 2019 Financial Results NewLink Genetics Corporation Nasdaq: NLNK May 8, 2019
Slide 2: Agenda
•Lisa Miller, Director of Investor Relations Agenda • Charles J. Link, Jr, MD, Chairman, CEO & CSO •Eugene Kennedy, MD, Chief Medical Officer • Carl Langren, Chief Financial Officer 2
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,
Slide 4: Clinical Programs
Recurrent NLG207 plus paclitaxel in recurrent ovarian cancer ovarian cancer . Encouraging GOG Phase 2 results presented at AACR in April 2019 NLG207 Front-line diffuse Indoximod plus radiotherapy for pediatric patients with DIPG intrinsic pontine . Early data show all patients demonstrated initial s
Slide 5: Other Opportunities
Other Opportunities Ebola VSV-ZEBOV (V920) vaccine . Merck has announced that the EMA has recently accepted the Marketing Authorization Application (MAA) of this Ebola vaccine candidate . Merck also announced in 2018 that they had begun a rolling BLA submission with expected filing completion in 201
Slide 6: NLG207 Ovarian Cancer
NLG207 Ovarian Cancer NLG207 (formerly CRLX101) Approximately Roughly 70 percent . Nanoparticle formulation of the 22,530 of patients diagnosed with ovarian cancer topoisomerase 1 inhibitor camptothecin women will be diagnosed 3 with ovarian cancer in 20181 will have a recurrence . Acquired from Cer
Slide 7: Financial Position
Financial Position Q1 2019 End Cash and Equivalents $113.2 Million Average Quarterly Cash Use Projected ~$10 Million Cash Runway Projected Through 2021 Shares Outstanding as of March 31, 2019 37.28 Million 7
Slide 8: NewLink Genetics: Key Takeaways
NewLink Genetics: Key Takeaways Targeting Indications of Need Strong Cash Position Presentations 2019 . Current clinical development Cash on hand at Q1 end program focus: $113.2 million April 2019: Encouraging Phase 2 results for NLG207 in recurrent . NLG207 in recurrent ovarian cancer Estimat
Slide 9: Q & A
Q & A 9